Financial Data and Key Metrics Changes - Fiscal year 2025 marked a record-setting year for the company, with fourth-quarter revenue reaching $7 million, the highest in the company's history, representing an 8.1% increase year-over-year and a 13.5% increase quarter-over-quarter [4][16] - Gross margin improved to 64% in the fourth quarter, up from 48% in the same quarter last year, and 55% for the full fiscal year, an increase from 49% in fiscal year 2024 [4][17] - Adjusted EBITDA loss narrowed to $316,000 in the fourth quarter, a significant improvement from a loss of $1.7 million in the same quarter last year [6][19] - Cash position improved to $10.8 million as of April 30, 2025, compared to $3.5 million at the end of fiscal year 2024 [20] Business Line Data and Key Metrics Changes - The BioStrand segment experienced exceptional growth, increasing over 180% year-over-year, with gross margins approaching 90% [5][17] - Canadian business showed strong growth, with sales orders reaching $4.3 million in the fourth quarter, more than double historical quarters, and year-over-year sales in Canada increased by 47% [6][17] Market Data and Key Metrics Changes - The company is actively divesting its Dutch subsidiary, with the process in the final stages, which is expected to streamline operations and generate additional cash [7][8] - The company plans to rebrand shortly after the divestiture to reinforce its position as a bio-native AI platform [9] Company Strategy and Development Direction - The company is shifting from a service-oriented model to a customizable platform-driven business, focusing on AI and data integration in drug discovery [9] - Strategic collaborations have been established, including partnerships with Ribopro and a publicly traded technology company, aimed at enhancing therapeutic development offerings [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering the new fiscal year with a financially disciplined position to support growth, driven by strong cash position and validated AI economics [20] - The company anticipates continued growth in its core capabilities and expects the trend of increased inquiries related to IND applications to persist [35] Other Important Information - The FDA's plans to phase out animal testing for monoclonal antibodies align with the company's Lens AI capabilities, which predict toxicity and immune response [11] - The company regained compliance with Nasdaq's minimum bid price requirement, reflecting growing market confidence [13] Q&A Session Summary Question: What should be expected for the clinical development of GLP-one peptides? - The company is working with two partners on drug product manufacturing and unique administration routes, with plans to bring in a financial sponsor for clinical trials [22][24] Question: What milestones are needed to recognize payments from the biotech partner on oncology assets? - Initial payments are expected to be visible in the second quarter, with no unusual deal-breaking milestones [25][27] Question: What traffic has been seen for services since the FDA's guidance on AI-based systems? - There has been a significant increase in inquiries related to IND applications, particularly for immunogenicity and epitope mapping [29][35] Question: How far along is the divestment of European facilities? - The divestment process is in the final stages, with a dedicated buyer and no expected detrimental impact on the Canadian facility [36][39]